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was their use of antidiabetic medications in the 90 days prior to
their HbA1c test. All results are descriptive in nature. RESULTS:
A majority of the patient population was male in their mid-60.
Hypertension (51%) and ischemic heart disease (19%) were
commonly diagnosed co-morbidities. Of patients with type-2
diabetes, 30% received no antidiabetic medications, 41% were
treated with a single antidiabetic agent (e.g., metformin, sul-
fonylurea), while the remaining patients received combination
therapy. Over half of the patients who received some antidiabetic
medication had an HbA1c that did not meet the NICE recom-
mendation of 7.5% or less. Interestingly, more than 70% of the
patients who received either insulin alone or in combination with
oral antidiabetic medications (s) had HbA1c values greater than
7.5%. CONCLUSIONS: Despite recent important advances in
pharmacotherapy for type-2 diabetes, glycemic control remains
suboptimal for a large percentage of patients in the UK. In order
to adhere to NICE recommendations, health care professionals
may wish to consider further additive or alternative treatment
options.
Health Related Quality of Life Based Patient Reported
Outcomes: Session 2
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OBJECTIVE: The link between clinical responses to treatment
and changes in the Dermatology Life Quality Index (DLQI) has
not been established in moderate to severe plaque psoriasis. The
objective of this study was to determine changes in DLQI total
score that correlate with clinical improvement in this patient
group treated with adalimumab. METHODS: A randomized,
double-blind, placebo-controlled, multi-center clinical trial for
the treatment of moderate to severe plaque psoriasis with adal-
imumab was conducted. Patients (n = 147) were randomized to
adalimumab 40mg every other week (eow), adalimumab 40mg
weekly, or placebo, and were followed for up to 12 weeks. The
correlation between changes in the DLQI total score and clini-
cal assessment of psoriasis severity, using the Psoriasis Area and
Severity Index (PASI), was evaluated. To determine a minimum
clinically important difference (MCID) for DLQI total score, a
change of between 25% and 49% in the PASI score was used.
Three standard distributional methods were used to determine
the MCID for DLQI total score. RESULTS: The MCID for DLQI
total score ranged from 2.3 to 4.0. This represents changes in
dermatologic functional limitations in patients who achieved at
least a 25% improvement in PASI score. In patients who had
achieved at least a 75% improvement in PASI score, mean
improvement in DLQI total score was 10.8 points in patients
randomized to adalimumab 40mg eow, 11.5 points in those who
had received adalimumab 40mg weekly, and only 1.3 points in
the placebo group. CONCLUSION: The MCID for DLQI total
score established in this study was between 2.3 to 4.0. Given that
adalimumab-treated patients experienced a mean change in
DLQI of at least 10 points, improvement in dermatologic-related
functional limitations with this treatment is likely above the
MCID.
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OBJECTIVES: Fatigue is a common, distressing symptom of
ankylosing spondylitis (AS), a chronic inﬂammatory disease pre-
dominantly affecting the spine. This study evaluated whether
adalimumab therapy reduced fatigue in patients with active AS.
METHODS: A randomized, placebo-controlled, Phase III study
of adalimumab was conducted in Canada with patients with
active AS who had experienced an inadequate response to at 
least one NSAID or disease-modifying, antirheumatic drug
(DMARD). Patients received either adalimumab 40mg every
other week or placebo for 24 weeks. Fatigue was assessed by the
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F), a widely used measure of fatigue in chronic illnesses,
and the fatigue item of the BATH AS Disease Activity Index
(BASDAI), a well-established instrument used in clinical studies
to evaluate AS disease activity. FACIT-F scores range from 0–52,
with higher scores representing less fatigue, and a >= 3-point
change considered clinical meaningful. The BASDAI fatigue item
ranges from 0–10, with lower scores reﬂecting less fatigue.
RESULTS: A total of 82 patients (38 on adalimumab, 44 on
placebo) were enrolled. At baseline, both arms had comparable
demographics and disease characteristics. Baseline FACIT-F
(adalimumab 24.4, placebo 23.6) and BASDAI fatigue (adali-
mumab 6.3, placebo 6.9,) were similar between arms. After 12
weeks, adalimumab patients had achieved statistically signiﬁ-
cantly greater improvement in FACIT-F than placebo patients
(6.9 vs. 1.7, p = 0.005). In addition, patients on adalimumab had
achieved statistically greater improvement in BASDAI fatigue vs.
placebo (-1.7 vs. -0.5, p = 0.006). Even greater improvements
were achieved at 24 weeks in adalimumab vs. placebo patients
for both measures (FACIT-F, 7.8 vs. 2.6, p = 0.013, and BASDAI
fatigue, -1.9 vs. -0.5, p = 0.006). Improvements in FACIT-F at
both 12 and 24 weeks were clinical meaningful. CONCLU-
SIONS: These results indicate adalimumab treatment provides
AS patients with statistically signiﬁcant and clinically meaning-
ful improvements in fatigue compared with placebo.
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OBJECTIVES: To describe the observed changes in quality of life
and bother associated with LUTS at one year from baseline
assessment in a sample of Italian women. METHODS: The
FLOW study is a two-year observational investigation aimed at
evaluating prevalence, clinical progression and QoL impact of
female LUTS. Women aged ≥ 18 years, not pregnant, with LUTS
for ≥3 months and negative dipstick were consecutively enrolled
in 39 Italian Urology Centres. Symptoms and QoL were assessed
by: ICIQ-LF, W-IPSS and SF-36. Differences between the ques-
tionnaires’ scores at baseline and follow-up visits were calculated
to assess deterioration or improvement in QoL. Here we refer to
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the ﬁrst 12-month observational period. Out of 505 total sub-
jects enrolled at (12 months) follow-up, 467 patients fully com-
pleted ICIQ-LF. The average variation observed in patients’
reported overall “impact of symptoms” was -1.92 (SD 3.36;
range -7; 10), suggesting a reported improvement in QoL from
baseline. The frequency of women who complained of urine
leakage shows a signiﬁcant decrease from baseline to follow up
(68% Vs 55.6%). Consistently, the number of patients com-
plaining of limited activities due to urinary leakage decreased
from 56.5% to 42%. The W-IPSS was compiled by 83% of all
subjects. For all symptoms considered, greater improvement in
QoL was observed were symptoms showed higher remission
rates and lower persistency and incidence rates. An overall
improvement was conﬁrmed also by SF-36. RESULTS: 49.2%
of patients at follow-up reported a good health status (to various
degrees) versus 10.7% at baseline. CONCLUSION: According
to ICIQ-LF and W-IPSS an overall condition improvement was
registered at 12 months from baseline with respect to all LUT
symptoms (storage, voiding and post-micturition categories). A
correlation between increased QoL and observed symptoms
remission rates was detected by all questionnaires.
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OBJECTIVE: Hemophilia treatment has prolonged patients’ life
expectancy and is now focused on improving their Health-
Related Quality-of-Life (HRQoL). We evaluated HRQoL of
adult hemophilic patients without inhibitors. METHODS: The
Cost Of Care of HEmophilia (COCHE) study is a naturalistic,
multicenter, longitudinal study. Patients without inhibitors aged
>18 years were sequentially enrolled at 23 Italian Hemophilia
Care Centers. Information collected was on: socio-demograph-
ics, clinical, resource absorption (direct, indirect costs), HRQoL
(intangible costs) and treatment satisfaction. The following
results pertain to the HRQoL evaluated with two generic instru-
ments: EuroQol (EQ-5D) and Short Form-36 (SF-36). RESULTS:
232 patients were enrolled (median age = 34.3, ranging from 18
to 74), 86.6% with hemophilia A, 72.4% severely affected. At
the time of enrolment 81.0% of patients had chronic hepatic C,
25.0% hepatitis B, 15.9% HIV infection. Most of the patients
(87.8%) reported some orthopedic problems. Target joints were
present in 57.0% of patients. Bleeding occurred on average 2.10
times per patient/month (median 1.44, ranging from 0 to 26).
EQ-5D proﬁle showed that 77.9% of patients complained of
moderate or extreme “pain/discomfort”, 63.5% had problems
with “mobility”, 48.9% were anxious or depressed, 40% had
problems in doing “usual activities”, 12.2% problems with “self-
care”. EQ-Visual Analogue Scale had a mean value of 66.2
(median 70.0, ranging from 9 to 100). The mean+/-SD utility
score was 0.7+/-0.2 (median 0.7, ranging from -0.2 to 1). These
results were conﬁrmed by the SF-36: in particular, the mean+/-
SD Physical Component Summary score was 36.9+/-10.7
(median 35.2, from 15.2 to 55.0); the mean+/-SD Mental Com-
ponent Summary score was 50.2+/-11.8, (median 52.8, from
15.5 to 68.1). CONCLUSION: Hemophilic patients without
inhibitors showed impaired levels of general HRQoL. In partic-
ular the physical component of HRQoL was sensitively com-
promised; by contrast the mental component was relatively good
in comparison to the general Italian male population.
Cost Evaluation Studies in Diabetes and Neurological
Disorders
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OBJECTIVES: This study assessed the economic value of using
SPECT-DaTSCAN (123I-FP-CIT) in comparison with current
clinical judgment, in the diagnosis of patients with clinically
uncertain Parkinsonism in Italy. METHODS: A cost-effective-
ness analysis was based on a Markov model, comparing a cohort
of patients following a diagnostic pathway including or exclud-
ing DaTSCAN, using a time horizon of 5 years. The model was
populated with direct medical costs (drugs, tests, exams, hospi-
tal admissions, management of adverse events) associated with
diagnosis and treatment, diagnostic accuracy (sensitivity: 97%,
speciﬁcity: 100%), the underlying prevalence of diseases in the
tested population (estimated to be 49%), rates of adverse events,
therapy progression and death. Effectiveness was expressed as
the (gain in) number of years of appropriate therapy per patient.
Model input values were estimated using a double round Delphi
panel performed with 12 Italian specialists. Diagnostic accuracy,
adverse event rates and mortality rates were based on published
studies. RESULTS: The current diagnostic pathway produced on
average 2.3 “adequately treated years” (ATYs) per patient at an
estimated cost of €8893 to the health care system over 5 years.
The DaTSCAN pathway generated on average 4.1 ATYs per
patient at an estimated cost of €8410. Use of DaTSCAN rather
than current diagnostic practice generated an additional 1.8
ATYs at a cost saving of €482 per patient over 5 years. Dis-
counting at 5%, the cost saving became €372 per patient over 5
years. If the use of DaTSCAN decreased other diagnostic work-
up costs by €450 (estimated by clinical expert), cost savings
became €932 (undiscounted) per patient tested. The result is sen-
sitive to the proportion of patients tested. CONCLUSION: The
analysis suggests that using DaTSCAN in patients with clinically
uncertain Parkinsonism is an economically attractive interven-
tion. Greater amounts of time on appropriate therapy are
achieved at less cost to the health care system.
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OBJECTIVES: Self monitoring of blood glucose (SMBG) has
been shown to improve glycemic control of type 2 diabetes in
previous studies (HbA1c improved by 0.3–0.6% with SMBG
versus no SMBG, depending on treatment received) However, the
cost of testing supplies is high and cost-effectiveness has not been
evaluated. METHODS: A validated model (CORE Diabetes
model) projected improvements in lifetime quality-adjusted life
years (QALY), long-term costs, and cost-effectiveness of SMBG
versus no SMBG. Markov/Monte Carlo modeling simulated pro-
gression of complications (cardiovascular, neuropathy, renal and
